anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants are seen weekly for six weeks for therapy. At visits 2, 4, and 6 they also complete ratings.
The experimental group will receive 5 treatments followed by a final assessment on the 6th visit over a 3 week period: participants will receive manual lymphatic drainage for 40 minutes. They will then put on an Adjustable Compression sleeve (Juzo varocare adjustable compression system). Patients will be re-measured before the fourth treatment and again on session 6. At this point patients will receive a standard arm compression sleeve. This will be worn in alternation with their adjustable compression sleeve over the following 6 months. Patient will have their limb volume re-measured at the 6 month review.

The control group will receive 5 treatments followed by a final assessment on the 6th visit over a 3 week period: participants will receive manual lymphatic drainage for 40 minutes. They will then have their arm wrapped in Coban compression bandaging which will stay on until their next treatment. This will occur twice weekly for a period of 3 weeks. Patients will be Re-measured before the fourth treatment and again on session 6. At this point they will attend occupational therapy where they will receive 2 standard arm compression sleeves. The patient wears 1 sleeve every day over the following 6 months. Patient will have their limb volume re-measured at the 6 month review.
Nurses will offer screening to all patients at EDs, aged 18-64 years old, identified as high-risk by a self-administered questionnaire, not know to be HIV positive, accepting to participate by providing an informed consent and not being seen at ED for post-exposure prophylaxis or unstable medical illness. The questionnaire was previously tested in one ED. In case of reactive rapid test result, blood specimen will be collected for standard enzyme-linked immunosorbent assay and Western blot confirmation. A follow-up visit with an on-site infectious disease specialist will be arranged within the following 48 hours.
PROBLEM TO BE SOLVED: To obtain new purine L-nucleoside compounds and to provide a therapeutic use thereof. SOLUTION: The new purine L-nucleoside compounds are disclosed. Both the purine rings and the sugar are either modified and functionalized or both. The new compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions. The compositions may be used to treat an infection, an infestation, a neoplasm or an autoimmune disease. The new compounds may also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.
The DREAM (Diabetes Research, Education, and Action for Minorities) Project is a Community Health Worker (CHW) intervention to improve diabetic management and control among Bangladeshis with diabetes in New York City (NYC). For a two-arm, randomized controlled trial (RCT), investigators will recruit a sample of 256 participants, all of whom are 1) of Bangladeshi descent, 2) residing in NYC, 3) diagnosed with Type 2 diabetes mellitus (T2DM) and a recent Hemoglobin A1c (HbA1c) of ≥ 6.5, and 4) between the ages of 21-85. The treatment group receives a six-month CHW-led intervention consisting of five monthly group educational sessions, two one-on-one visits, and follow-up phone calls as needed from a CHW. The control group receives an introductory educational session only. Primary and secondary outcomes include clinical and behavioral measures, such as HbA1c and weight change, access to and utilization of care (i.e. appointment keeping and use of specialty care), and knowledge and practice of physical activity and healthful eating. Additionally, information regarding CHW characteristics, the processes and mechanisms for influencing healthful behavior change, and fidelity of the intervention are collected. Outcomes are measured at Baseline, 3-Months, 6-Months for both groups, and at 12-Months for the treatment group.
Study group consists of patients with cancer who are qualified for home enteral nutrition in Nutritional Counselling Center Copernicus in Gdansk. The control group will receive home enteral nutrition and placebo. The experimental group will receive home enteral nutrition and Lactobacillus plantarum 299v. The study is prospective and double-blind. The parameters for evaluation of nutritional status are: BMI, body mass analysis, level of total protein and albumin in blood serum, total lymphocyte count, NRS 2002 method. Assessment of the quality of life and tolerance of enteral diet will be done by questionaires.
A sheet of plastic adhesive material for use as a medical dressing is made from a composition prepared from polyisobutylene with or without mineral oil or petrolatum, and polyvinyl alcohol or gum acacia and/or a mixture of gelatine, pectin and sodium carboxymethyl-cellulose with or without benzocaine, or tetracycline and amphotericin.  In making the sheet the polyisobutylene component is heated, the other components are mixed therewith, the mixture is allowed to cool and the cooled mixture is passed through a roller mill and flattened in an hydraulic press.ALSO:A protective dressing, e.g. medicated dressing comprises a sheet of plastic adhesive material, the material being a blend of a water soluble or water swellable hydrocolloid and a water insoluble viscous elastic binder.  The sheet may be provided with a backing film.  The hydrocolloid may be polyvinyl alcohol, gum acacia, pectin, gelatin, carboxymethylcellulose, sodium carboxymethylcellulose, polyethylene glycol or carboxy polymethylene or a mixture thereof.  The binder may be natural rubber, silicone rubber, acrylonitrile rubber, polyurethane rubber, polyisobutylene or sucrose acetate butyrate.  The backing film may be polyethylene, polypropylene, polymers and copolymers of vinylidene chloride or fluorocarbon, or condensation products of ethylene glycol and terephthalic acid.  The medicaments specified are insulin, amphotericin, tetracycline benzocaine and triamcinolone acetonide.
OBJECTIVES: Sepsis is a life-threatening condition implicating an inadequate activation of the immune system. Platelets act as modulators and contributors to immune processes. Indeed, altered platelet turnover, thrombotic events, and changes in thrombopoietin levels in systemic inflammation have been reported, but thrombopoietin-levels in sepsis and septic-shock have not yet been systematically evaluated. We therefore performed a meta-analysis of thrombopoietin (TPO)-levels in patients with sepsis.
METHODS: Two independent reviewers screened records and full-text articles for inclusion. Scientific databases were searched for studies examining thrombopoietin levels in adult sepsis and septic-shock patients until August 1st 2022.
RESULTS: Of 95 items screened, six studies met the inclusion criteria, including 598 subjects. Both sepsis and severe sepsis were associated with increased levels of thrombopoietin (sepsis vs. control: standardized mean difference 3.06, 95 % CI 1.35-4.77; Z=3.50, p=0.0005) (sepsis vs. severe sepsis: standardized mean difference -1.67, 95 % CI -2.46 to -0.88; Z=4.14, p<0.0001). TPO-levels did not show significant differences between severe sepsis and septic shock patients but differed between sepsis and inflammation-associated non-septic controls. Overall, high heterogeneity and low sample size could be noted.
CONCLUSIONS: Concluding, increased levels of thrombopoietin appear to be present both in sepsis and severe sepsis with high heterogeneity but thrombopoietin does not allow to differentiate between severe sepsis and septic-shock. TPO may potentially serve to differentiate sepsis from non-septic trauma and/or tissue damage related (systemic) inflammation. Usage of different assays and high heterogeneity demand standardization of methods and further large multicenter trials.
Six ambulances from five different Emergency Medical Service (EMS) districts are equipped with a portable telemedicine system. In cases of suspected acute coronary syndrome (including STEMI), the paramedics can use this system to contact a so called "tele-EMS physician" after consent of the patient is obtained. The tele-EMS physician has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.

The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS.
Low back pain is characterized by pain and represents a change in health that affects mainly adults, although electrostimulation represents an important tool in the treatment of patients with chronic nonspecific low back pain, the clinical efficacy of the interferential current used in physiotherapy still lacks reinforcement for clinical validation. In this way, the present study evaluated whether the use of interferential current contributes to reducing chronic low back pain and analyzed whether the electrotherapeutic protocol can benefit the physical functionality of patients with chronic low back pain. 24 individuals were evaluated, with low back pain for more than 12 weeks and aged between 12 and 65 years. The current used in the lumbar region of the participants was of the tetrapolar interferential type and the stimulation mode was the automatic vector, carrier of 4,000 HZ, modulation frequency (AMF) of 50 HZ, sweep frequency of SWEEP of 20HZ. The assessment of pain and functionality was performed using the data collection instrument, the Visual Analogue Pain Scale (VAS), Rolland Morris Disability Questionnaire (RMDQ) and the Owestry Disability Questionnaire (ODQ) respectively. Data analysis was performed using the JAMOVI 2.2.5 software. Our data showed that individuals with interferential current showed significant improvement in pain relief, as well as in the functional pattern of pain improvement. The present study demonstrates that treatment with interferential current promotes chemical improvement in participants, which opens up new perspectives on the use of this therapeutic approach.
The invention discloses an active peptide, matrine compound, composition and application thereof in preparing products for improving cell viability. The active peptide has an amino acid sequence shown in SEQ ID NO. 1. The matrine compound is selected from structures shown in formula I, formula II, formula III or formula IV. The composition comprises gamma-aminobutyric acid, an active peptide with an amino acid sequence shown in SEQ ID NO 1, a matrine compound with a structure shown in a formula I, a matrine compound with a structure shown in a formula II, a matrine compound with a structure shown in a formula III and a matrine compound with a structure shown in a formula IV. The active peptide, matrine compound or composition of the invention has the functions of improving the activity of skin keratinocytes, promoting the expression or secretion of collagen, elastin and/or fibronectin of the skin keratinocytes, inhibiting the contraction of skin muscles, reducing skin fine lines and skin wrinkles, and the like.
JNJ-37822681 oral capsule will be administered at a starting dose of 20 mg once daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14. Matching Placebo will be administered orally in the evening for 14 days (12 hour post JNJ-37822681 administration).
PURPOSE:An animal parasitic ovicidal agent, consisting essentially of o- dichlorobenzene and quinomethionate and having more powerful parasitic ovicidal effect than the conventional ortho agent. CONSTITUTION:An animal parasitic ovicidal agent consisting essentially of quinomethionate expressed by the formula (chemical name; S,S-6- methylquinoxaline-2,3-diyl.dithiocarbonate) and o-dichlorobenzene. The mixing weight ratio thereof is preferably about 40-90wt% o-dichlorobenzene to about 0.1-15wt% compound expressed by the formula. An emulsion is optimum for the dosage form. Normally, various parasitic eggs, e.g. mawworm, tapeworm, liver fluke, etc., contained in excrements, etc., in a barn can be killed. The agent is more effective than the conventional ortho agent.
The control group received traditional physical therapy program in the form of strengthening exercise, stretching , and range of motion exercise.for the affected digits and wrists. for one hour, three sessions per week for 8 weeks.
The invention discloses a herb bag for cooking soup. The herb bag is characterized by comprising a sealable container with herb mixtures, and the herb mixtures comprise the following raw materials in parts by weight: Chinese wolfberry 10, epimedium 5, longan pulp 10, radix dipsaci 5, ginseng 15, corn stigma 2, pangolin 5, turtle shell 5, Cordyceps Sinensis 10, lotus seeds 15, Pinellia ternata 3, Evodia rutaecarpa 1, root of Inula japonica Thunb. 1, Eclipta prostrata 1, Angelica sinensis 10, and papaya 30. The herb bag for cooking soup has the efficacies of health care, fatigue resistance, nourishing liver and kidney, invigorating spleen and replenishing qi, enriching essence and tonifying Yang, and strengthening bone, and is suitable for people with symptoms such as liver and kidney Yin deficient, backache and bone pain, dizziness, limb numbness, impotence, low spirits, less sleep and much dream and forgetfulness. The herb bag has the effect of strengthening the body, and especially is more effective for male. The invention also discloses an application method of the herb bag for cooking soup.
The invention discloses a dog parvovirus attenuated vaccine strain and application thereof. In the invention, the separated dog parvovirus virulent strain is cultivated in a cell subculture mode to obtain the dog parvovirus attenuated vaccine strain. The microbial preservation number is CGMCC No.3841. The test on safety and immunogenicity indicates that the attenuated vaccine strain CPV-YNR can protect the dog subjected to the attack of homologous virulent strain and has favorable immunogenicity. The attenuated vaccine strain CPV-YNR can be used for preparing a single vaccine or combined vaccine, and can effectively prevent or treat diseases caused by dog parvovirus. The attenuated vaccine strain CPV-YNR has the advantages of stable heritability, enduring immunity, favorable effect, high safety and reliability, long storage time and the like.
Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
All women with POP and concomitant overt or occult USI, who underwent the novel anterior TVM surgeries, were enrolled in this study. Medical records, including urodynamic studies, questionnaires and 3-day bladder diaries, were retrospectively reviewed. Linear regress analysis was used to identify factors that were responsible for the changes in pad weights from baseline \[i.e., 100 \* (postoperative pad weight - baseline pad weight)/baseline pad weight\].
The innate immune regulator stimulator of interferon genes (STING) mediates self-DNA sensing and leads to the induction of type I interferons and inflammatory cytokines, which promotes the progression of various inflammatory and autoimmune diseases. Innate immune system plays a critical role in regulating obesity-induced islet dysfunction, whereas the potential effect of STING signaling is not fully understood. Here, we demonstrate that STING is mainly expressed and activated in islet macrophages upon high-fat diet (HFD) feeding. Sting-/- alleviates HFD-induced islet inflammation by inhibiting the expression of pro-inflammatory cytokines and the infiltration of macrophages. Mechanically, palmitic acid incubation promotes mitochondrial DNA leakage into the cytosol and subsequently activates STING pathway in macrophages. Additionally, STING activation in macrophages impairs glucose-stimulated insulin secretion by mediating the engulfment of β cell insulin secretory granules. Pharmacologically inhibiting STING activation enhances insulin secretion to control hyperglycemia. Together, our results reveal a regulatory mechanism in controlling the islet inflammation and insulin secretion in diet--induced obesity and suggest that selective blocking of the STING activation may be a promising strategy for treating type 2 diabetes.
PURPOSE: A medicinal composition containing polylysine and glycerol monolaurate is provided to sterilize H.P bacteria without damage to oral cavity. CONSTITUTION: A composition for sterilizing Helicobacter pylori contains polylysine and glycerol monolaurate. The concentration of the composition is 350mg/100ml-1,000mg/100ml. The composition further contains pharmaceutically acceptable carrier. The composition is manufactured in the form of solution, solid, oil phase, powder, tablet, capsule, or gel. A method for preparing the composition for sterilizing helicobacter pylori comprises: a step of mixing polylysine and glycerol monolaurate; a step of cooling by room temperature; and a step of adding menthol crystal powder.
PURPOSE:To obtain a bath agent containing a coexisting alkali salt and aluminum salt, by blending an alkali salt which is a principal ingredient of the bath agent with an aluminum salt, e.g. alum, etc., and further adding a hydroxycarboxylic acid thereto to prevent the precipitation of aluminum ions. CONSTITUTION:A bath agent, obtained by blending an alkali salt, e.g. sodium hydrogencarbonate, sodium sulfate, etc., which is a principal ingredient of the bath agent with an aluminum salt, e.g. alum, aluminum sulfate, etc., and further adding a hydroxycarboxylic acid, e.g. citric acid, tartaric acid, etc., or oxine-5- sulfonic acid, etc., thereto to prevent the precipitation and deposition of aluminum ions and containing the simultaneously coexisting alkali salt and aluminum salt in water. Although aluminum ions readily form precipitates even in a very slight alkaline aqueous solution under environmental condition, e.g. natural hot spring, etc., the above-mentioned bath agent is capable of providing the coexisting alkali salt and aluminum salt in water in a general household bath and efficacious for athele's foot and chronic constipation.
PCT No. PCT/JP93/01524 Sec. 371 Date Jan. 11, 1995 Sec. 102(e) Date Jan. 11, 1995 PCT Filed Oct. 21, 1993An active oxygen free radical scavenging agent superior in scavenging active oxygen free radicals produced in organisms is provided. The active oxygen free radical extinguishing agent includes green tea leaf extract containing epigallo catechin gallate and sunflower seed extract containing chlorogenic acid. When administrating green tea leaf extract and sunflower seed extract simultaneously as disclosed in the embodiment, the active oxygen free radical scavenging effect greatly excels the same when said two kinds of active oxygen free radical scavenging agents are separately administrated as shown in reference 2 and reference 3, or the same when rhubarb is administrated as shown in reference 4.
Provided is an immunogenic composition comprising a recombinant peptide and protein. The recombinant peptide and protein comprise a coronavirus antigen and immunogen, for example, an S protein peptide of a SARS-CoV-2 coronavirus beta (B.1.351) variant or a fragment, a variant or a mutant thereof, such as a chimeric antigen and immunogen comprising a receptor-binding domain of the beta variant and an S protein peptide sequence of an original strain or other variants. The immunogenic composition comprises a secreted fusion protein, the secreted fusion protein comprising a soluble coronavirus antigen. The soluble coronavirus antigen protein is connected, by means of an in-frame fusion, to a C-terminal moiety of a collagen capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. The provided immunogenic composition can be used for generating an immune response, for example, used as a vaccine for the prevention of coronavirus infections, such as infections by SARS-CoV-2 original (Hu-1), alpha, beta, gamma, delta, omicron strains and/or other strains. The provided immunogenic composition can be used in a vaccine composition, for example, as part of a prophylactic and/or therapeutic vaccine. Also provided are methods for producing the recombinant peptide and protein, methods for the prevention, treatment and/or diagnosis, and a related kit.
This is a research project involving patients in Medical Oncology Department of Affiliated Cancer Hospital of Xiangya School of Medicine Central South University. Retrospective study of 40 patients with advanced non-squamous non-small cell lung cancer (NSCLC) using Crizotinib ROS1 rearrangement positive mutation was conducted to observe the efficacy and safety of Crizotinib regimen in the real world.Exploratory research contents are as follows: 1. Consistency between tissue gene test (NGS) and plasma gene test (NGS) at the initial diagnosis; 2. Consistency between NGS and plasma gene test (NGS) at the progression of clozotinib treatment; 3. Drug resistance mechanism of clozotinib in ROS1 rearrangement positive NSCLC; 4. Plasma drug resistance. Large panel dynamic driven gene mutation analysis was used to construct disease progression risk model.
After interruption of blood supply to central nervous system tissue, cerebral edema sets in. It has been shown that restoring blood flow to injured areas of the central nervous system after the onset of edema does not result in blood reperfusing the tissue. A composition and method for treating injured central nervous tissue, or preventing injury to central nervous system tissue is provided. The composition is generally an amphipathic lipid in an oil solution. The method provides for withdrawing cerebrospinal fluid from the subarachnoid spaces around the tissue to be treated or protected, and replacing that fluid with an approximately equivalent volume of the amphipathic lipid in oil composition. The treatment can be augmented with agents that suppress production of cerebrospinal fluid, or with other known agents.
Across centers, there is a variation in standard of care for the preferred device and interface to deliver continuous positive airway pressure (CPAP) to support neonatal functional residual capacity. CPAP, a type of noninvasive respiratory support, is commonly delivered to neonates by mechanical ventilators or underwater bubble devices (bubble CPAP). Variation also exists with the tubing used to deliver CPAP. One commonly used nasal interface is the RAM cannula (Neotech, Valencia, CA), made of a soft material with thin tubing walls and is designed to provide 60-80% occlusion of the nares. This contrasts with the occlusive interface intended to provide complete seal.

To provide evidence for standardization of CPAP delivery, clinical trials are needed to assess which modality of CPAP delivery is optimal for neonates with respiratory distress syndrome who are \> 32 weeks and \<37 weeks gestational age, an understudied population. The investigators propose to use electrical impedance tomography (EIT) paired with esophageal balloon manometry to assess neonatal lung physiology when supported with different modalities of CPAP. Furthermore, participants will be randomly assigned to A) physiology based CPAP vs B) one size fits all approach. The subjects will remain on the assigned modality of CPAP for the remainder of their respiratory distress syndrome treatment, and researchers will track which modality of CPAP results in a shorter CPAP treatment period and if this is expected based on the lung physiology data collected.